7 Popovic M. et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV–III) from patients with AIDS and pre-AIDS //
8 Sarngadharan M. et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV–III) in the serum of patients with AIDS //
9 Gao F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes //
10 D’arc M. et al. Origin of the HIV-1 group O epidemic in western lowland gorillas //
11 Chen Z. et al. Genetic characterization of new West African simian immunodefciency virus SIVsm: geographic clustering of household-derived SIV strains with human immuno-defciency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop //
12 Kalish M. et al. Central African hunters exposed to Simian immunodefciency virus //
13 Gilbert T. et al. The emergence of HIV/AIDS in the Americas and beyond //
14 Пиневич А. В., Сироткин А. К., Гаврилова О. В., Потехин А. А.
15 Ярилин А. А.
16 Атлас по медицинской микробиологии, вирусологии и иммунологии: Учебное пособие для студентов медицинских вузов / под ред. А. А. Воробьева, А. С. Быкова. М.: Медицинское информационное агентство, 2003. 236 с.
17 Doitsh G. et al. Cell death by pyroptosis drives CD4 T– cell depletion in HIV-1 infection //
18 The Durban Declaration //
19 De Clercq, E. The history of antiretrovirals: key discoveries over the past 25 years //
20 Volberding P. et al. Zidovudine in asymptomatic human immunodefciency virus infection. A controlled trial in persons with fewer than 50 °CD4-positive cells per cubic millimeter //
21 Dournon E. et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex //
22 Connor E. et al. Reduction of maternal-infant transmission of human immunodefciency virus type 1 with zidovu-dine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group //
23 Larder B, Kemp A. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) //
24 Hammer S. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodefcien-cy virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team //
25 Gulick R. et al. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodefciency virus infection and prior antiretroviral therapy //
26 Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies //
27 Weller S., Davis K. Condom effectiveness in reducing heterosexual HIV transmission //
28 Townsend C. et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
29 Коалиция по готовности к лечению. Закупки АРВ-препаратов в 2014 году: хроника децентрализации. Результаты мониторинга закупок и предоставления АРВ-препаратов в РФ. Санкт-Петербург, 2015. Публикация доступна на сайте http://itpcru.org
30 Hutter G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation //
31 Hutter G., Thiel E. Allogeneic transplantation of CCR5-defcient progenitor cells in a patient with HIV infection: An update after 3 years and the search for patient no. 2